Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA

by Sandra Wallerek, Jens Benn Sørensen
Published 2015-06-01

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.

by Ida Kappel Buhl, Eric Santoni-Rugiu, Jesper Ravn, Anker Hansen, Ib Jarle Christensen, Thomas Jensen, Bruce Pratt, Jon Askaa, Peter Buhl Jensen, Steen Knudsen, Jens Benn Sørensen
Published 2018-01-01

Very Early Response Evaluation by PET/MR in Patients with Lung Cancer—Timing and Feasibility

by Natasha Hemicke Langer, Seppo W. Langer, Helle Hjorth Johannesen, Adam Espe Hansen, Junia Costa, Thomas Levin Klausen, Julie Forman, Anders Olin, Sine Hvid Rasmussen, Jens Benn Sørensen, Johan Löfgren, Andreas Kjær, Barbara Malene Fischer
Published 2019-03-01

Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative

by Simon Ekman, MD, PhD, Pia Horvat, PhD, Mats Rosenlund, PhD, Anne Mette Kejs, MSc, Dony Patel, PhD, Ariadna Juarez-Garcia, PhD, Laure Lacoin, PharmD, Melinda J. Daumont, PhD, John R. Penrod, PhD, Odd Terje Brustugun, MD, PhD, Jens Benn Sørensen, MD, DMSc
Published 2021-05-01